ClinicalTrials.gg
RecruitingNCT07505771Updated Oct 7, 2026

A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced Cancer

A Phase 1 interventional study of 177Lu-IM-3050 in Solid Malignancies, sponsored by Immunome, Inc.. Recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Immunome, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 7, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
105
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

IM-3050-101 is a Phase 1 study to determine the safety and effectiveness of 177Lu-IM-3050 in treating participants with advanced cancer.

Read the detailed description

IM-3050-101 is a 2-part Phase 1 first-in-human (FIH), open-label, multicenter dose escalation and expansion study designed to determine the safety, tolerability, dosimetry, pharmacokinetics (PK), and preliminary anti-tumor activity of the radiopharmaceutical 177Lu-IM-3050 in participants with FAP-expressing advanced solid tumors. Part A of the study is a dose escalation phase to evaluate the safety, tolerability, preliminary anti-tumor activity, radiation dosimetry, and PK from escalating repeated doses of 177Lu-IM-3050 to determine maximum tolerated dose (MTD) and/or recommended expansion dose of 177Lu-IM-3050. Part B of the study is an expansion phase to further evaluate safety and tolerability of 177Lu-IM-3050 at the candidate recommended dose.

02

Conditions studied

  • Solid Malignancies
03

In context

Lead sponsor

Immunome, Inc. is the lead sponsor of 11 studies on the registry; 5 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 years of age
  • performance status (ECOG PS) of 0, 1 or 2
  • Histological or cytological diagnosis of a solid tumor
  • Participants must be to or have relapsed after at least one prior standard therapeutic regimen. Participants must be relapsed or refractory to, have developed an intolerance to, or not be candidates for available therapies with established benefit.
  • Participants must have as per v.1.1 based on imaging performed during Screening.

    • During Part A only, participants without measurable disease per RECIST v1.1 are eligible if approved by Medical Monitor.
  • During screening, participants must have positive FAP PET/CT uptake as described in criteria for continuation of IM-3050 treatment.
  • Participants must have adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Participant has received certain prior radiation therapy as detailed in the protocol
  • Participant has undergone major surgery within 4 weeks or minor surgery within 2 weeks of starting 177Lu-IM-3050 or has known active central nervous system (CNS) primary tumor or and/or carcinomatous meningitis.
  • Participant has a known history of malignant primary brain tumor, or another primary solid or hematologic (other than that under study), unless the participant has undergone potentially curative therapy with no evidence of that disease for at least 2 years and approved by the Medical Monitor.

Exception: The time requirement does not apply to participants who underwent successful definitive resection of certain cancers.

  • Recent or ongoing serious infection or other significant medical condition as detailed in the protocol.
  • Participant has received an product or been treated with an investigational device within 30 days, or 5 half-lives prior to receiving the FAP PET/CT imaging tracer or 177Lu-IM-3050.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Dose Escalation: 177Lu-IM-3050

    177Lu-IM-3050 administered intravenously on a 6-week cycle

    Drug: 177Lu-IM-3050

  • Experimental
    Dose Expansion: 177Lu-IM-3050

    177Lu-IM-3050 administered intravenously on a 6-week cycle

    Drug: 177Lu-IM-3050

Interventions

  • Drug177Lu-IM-3050

    177Lu-IM-3050 is a FAP-directed radiopharmaceutical

06

What researchers measure

Primary outcomes

  1. Safety and tolerability of 177Lu-IM-3050 in participants with advanced solid tumors as measured by incidence of treatment emergent adverse events (TEAEs)

    Type, frequency, seriousness, and severity of adverse events (AEs) graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria version 6.0, including adverse events (SAEs), AEs leading to discontinuation, and deaths

    Time frame: From first dose of 177Lu-IM-3050 through at least 42 days following last dose of study treatment serious; up to approximately 5 years

  2. Determine the recommended dose of 177Lu-IM-3050 for further development

    Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE criteria version 6.0, including SAEs, AEs leading to discontinuation, and deaths

    Time frame: From first dose of 177Lu-IM-3050 to 42 days following last dose of study treatment; up to approximately 5 years

Secondary outcomes

  1. Time course of blood radioactivity of 177Lu-IM-3050

    Pharmacokinetic (PK) parameter: Area Under the Concentration Time Curve \[AUC\] in blood

    Time frame: Through 42-49 days following last dose of 177Lu-IM-3050

  2. Time course of blood radioactivity of 177Lu-IM-3050

    Pharmacokinetic (PK) parameter: Maximum Concentration \[Cmax\] in blood

    Time frame: Through 42-49 days following last dose of 177Lu-IM-3050

  3. Time course of plasma IM-3050

    PK parameter: Area Under the Concentration Time Curve \[AUC\] in blood

    Time frame: Through 42-49 days following last dose of 177Lu-IM-3050

  4. Time course of plasma IM-3050

    PK parameter: Maximum Concentration \[Cmax\] in blood

    Time frame: Through 42-49 days following last dose of 177Lu-IM-3050

  5. Evaluate the preliminary anti-tumor activity of 177Lu-IM-3050 in participants with advanced solid tumors

    Objective response rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Week 6 until disease progression or participant discontinuation from study

  6. Evaluate the preliminary anti-tumor activity of 177Lu-IM-3050 in participants with advanced solid tumors

    Complete response rate (CRR) as measured by RECIST v1.1

    Time frame: Week 6 until disease progression or participant discontinuation from study

  7. Evaluate the preliminary anti-tumor activity of 177Lu-IM-3050 in participants with advanced solid tumors

    Disease control rate (DCR) as measured by RECIST v1.1

    Time frame: Week 6 until disease progression or participant discontinuation from study

  8. Evaluate the dosimetry of 177Lu-IM-3050 in participants with advanced solid tumors

    Time activity curves in the organs (e.g., kidneys) and tumor lesions

    Time frame: From first dose of 177Lu-IM-3050 3050 in Cycle 1 up to 8 days after Cycle 3 (each cycle is 42 days) or until participant discontinuation, whichever is earlier

  9. Evaluate the dosimetry of 177Lu-IM-3050 in participants with advanced solid tumors

    Absorbed dose calculations based on time activity courses in organs and tumor lesions

    Time frame: From first dose of 177Lu-IM-3050 3050 in Cycle 1 up to 8 days after Cycle 3 (each cycle is 42 days) or until participant discontinuation, whichever is earlier

  10. Safety and tolerability of FAP PET/CT imaging tracer in participants with advanced solid tumors as measured by incidence of TEAEs

    Type, frequency, seriousness, and severity of AEs graded using the NCI-CTCAE v6.0, including SAEs

    Time frame: From dose of FAP PET/CT imaging tracer until end of study

07

Study locations

5 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Dec 2029, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2026
First posted
Apr 1, 2026
StartActual
Jun 19, 2026
Primary completionEst.
Dec 2029
CompletionEst.
Dec 2034
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • NovaCure LLC · Miami, United States
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    1 site added
    Show site
    • NovaCure LLC · Miami, United States

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07505771
Lead sponsor
Immunome, Inc.
Responsible party
Sponsor
First posted
Apr 1, 2026
Start date
Jun 19, 2026
Primary completion
Dec 2029 (estimated)
Completion
Dec 2034 (estimated)
Last update
Oct 7, 2026

Study contacts

Immunome Medical Monitor
Contact
info@immunome.com
425.939.7410

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion